Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USL311 Alone and with Lomustine in Advanced Solid Tumors and Relapsed/Recurrent GBM
NCT02765165Phase 2Terminated
- Sponsor
- Proximagen
- Start
- Apr 2016
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of usl311 in solid tumor and glioblastoma (GBM) (5 arms), sponsored by Proximagen. Primary endpoint: Maximum Tolerated Dose. Started Apr 2016; status: terminated.
02
Drugs
usl311
03
Conditions
solid tumorglioblastoma (GBM)
Beyond the preview
Go deeper on NCT02765165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02765165.